FDA Panel Unanimously Backs First New Vaccine Since 2023
A key Food and Drug Administration advisory committee voted unanimously on Thursday to recommend Moderna’s mRNA influenza vaccine for approval, marking the panel’s first endorsement of a new vaccine since 2023 and capping a months-long regulatory drama that exposed deep political divisions over vaccine policy.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of Moderna’s mFlusiva (mRNA-1010) outweigh the risks for adults ages 50 to 64, and separately for those 65 and older, according to NPR. The FDA has set a decision deadline of August 5, 2026, and while it is not bound to follow its advisory panels’ recommendations, it typically does.
A Rocky Road to Review
The unanimous vote stands in stark contrast to the vaccine’s tumultuous path to regulatory consideration. In February 2026, the FDA — then under vaccine chief Vinay Prasad — declined to review Moderna’s application, a highly unusual move that blindsided the company. Prasad claimed the trial was not adequately controlled, overruling FDA scientists who had previously agreed to the study design.
Following public backlash and a formal meeting with Moderna, the FDA reversed its decision two weeks later. Prasad and former FDA Commissioner Marty Makary — both of whom had enacted stricter regulatory standards for vaccines — have since left the agency.
“It’s such a breath of fresh air, considering what we’ve gone through with Robert F. Kennedy Jr.,” Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a former VRBPAC member, told NPR.
The Science Behind the Shot
Phase 3 trial data published in the New England Journal of Medicine showed that Moderna’s mRNA flu vaccine reduced the likelihood of influenza illness by 27% compared to a standard-dose flu vaccine in adults 50 and older. The vaccine uses the same messenger RNA technology proven in COVID-19 vaccines, providing instructions for the body to produce flu antigens and develop immunity.
Dr. Anna Durbin, director of the Center for Immunization Research at Johns Hopkins University and a VRBPAC member, emphasized the rigor of the studies. “There were no shortcuts taken. There was a full efficacy evaluation done per standard FDA guidance … phase 3 efficacy studies conducted in tens of thousands of individuals,” she said, as reported by STAT News.
No major safety issues were identified. Over 6 billion doses of mRNA vaccines have been administered globally since 2020, and Moderna stated that the vaccine “does not enter the cellular nucleus, does not interact with the genome … and does not persist in the body.”
A Heavy Flu Season
The recommendation comes amid a severe flu season. CDC data presented at the meeting showed at least 32 million flu cases, 390,000 hospitalizations, and 24,000 deaths in the U.S. during the 2025-2026 season. Approximately 85% of eligible individuals were not fully vaccinated against influenza.
One of the key advantages of mRNA technology is production speed. Traditional flu vaccines take about six months to manufacture, often forcing scientists to predict circulating strains well in advance. mRNA vaccines can be produced in two to three months, potentially improving strain-selection accuracy and vaccine efficacy.
Political Headwinds Remain
The vaccine review occurred under the second Trump administration, with HHS Secretary Robert F. Kennedy Jr. — a prominent anti-vaccine advocate — overseeing health policy. In August 2025, Kennedy pulled back nearly $500 million in federal contracts for mRNA vaccine development and gutted the CDC’s Advisory Committee on Immunization Practices (ACIP), replacing qualified members with anti-vaccine allies.
A federal judge has since issued a temporary injunction blocking Kennedy’s changes to ACIP, but the committee’s dysfunction raises questions about how usage recommendations — and thus insurance coverage — for the new vaccine would be determined.
Dr. Jesse Goodman, former director of FDA’s Center for Biologics Evaluation and Research, acknowledged the public trust challenges ahead. “It’s not going to change overnight,” he told NPR. “I’m sure there are people who are going to remain concerned about mRNA-based vaccines, and there will be people who spread erroneous information about it. However, people will also look at the evidence.”
What’s Next
The FDA will make a final decision by August 5. If approved, mFlusiva would be the first mRNA-based influenza vaccine on the U.S. market and the first new vaccine recommendation from VRBPAC since Pfizer’s RSV vaccine in May 2023. Moderna has indicated it could have doses available for the upcoming flu season.
The vote also signals a potential return to normal FDA advisory committee functioning after a period of political interference. Michael Abrams, a senior researcher with Public Citizen, urged the agency to “frequently convene this committee as well as many other expert advisory committees the agency, since January 2025, has insufficiently utilized.”
For a nation weary of flu seasons and hungry for better protection, the unanimous recommendation offers a measure of hope — provided the remaining regulatory and political hurdles can be cleared.